![Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance | Oncogene Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance | Oncogene](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fonc.2015.152/MediaObjects/41388_2016_Article_BFonc2015152_Fig1_HTML.jpg)
Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance | Oncogene
![Frontiers | Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons | Molecular Neuroscience Frontiers | Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons | Molecular Neuroscience](https://www.frontiersin.org/files/Articles/902572/fnmol-15-902572-HTML/image_m/fnmol-15-902572-g001.jpg)
Frontiers | Artesunate Alleviates Paclitaxel-Induced Neuropathic Pain in Mice by Decreasing Metabotropic Glutamate Receptor 5 Activity and Neuroinflammation in Primary Sensory Neurons | Molecular Neuroscience
![Paclitaxel <BR>Antineoplastic Agent <BR>6 mg / mL,Intravenous Injection <BR>Multiple Dose Vial 50 mL< Paclitaxel <BR>Antineoplastic Agent <BR>6 mg / mL,Intravenous Injection <BR>Multiple Dose Vial 50 mL<](https://sep.yimg.com/ay/yhst-12533177228474/paclitaxel-antineoplastic-agent-6-mg-ml-intravenous-injection-multiple-dose-vial-50-ml-teva-00703476801-28.gif)
Paclitaxel <BR>Antineoplastic Agent <BR>6 mg / mL,Intravenous Injection <BR>Multiple Dose Vial 50 mL<
FOGLIO ILLUSTRATIVO: INFORMAZIONI PER L'UTILIZZATORE Paclitaxel Teva 6 mg/ml concentrato per soluzione per infusione Paclitaxe
![Predominant bands in the Raman spectra of a clinical paclitaxel solution from Teva Ind. and the assignment of relevant peaks. Predominant bands in the Raman spectra of a clinical paclitaxel solution from Teva Ind. and the assignment of relevant peaks.](https://www.researchgate.net/profile/Pierre-Yves-Collart-Dutilleul/publication/236932256/figure/fig2/AS:393145134141446@1470744512850/Predominant-bands-in-the-Raman-spectra-of-a-clinical-paclitaxel-solution-from-Teva-Ind_Q640.jpg)
Predominant bands in the Raman spectra of a clinical paclitaxel solution from Teva Ind. and the assignment of relevant peaks.
![Antineoplastic Agent <br> Paclitaxel 6 mg / mL<br> Intravenous Injection <br>Multiple Dose Vial 25 mL <br> teva 00703476701 Antineoplastic Agent <br> Paclitaxel 6 mg / mL<br> Intravenous Injection <br>Multiple Dose Vial 25 mL <br> teva 00703476701](https://sep.yimg.com/ay/yhst-12533177228474/antineoplastic-agent-paclitaxel-6-mg-ml-intravenous-injection-multiple-dose-vial-25-ml-teva-00703476701-23.gif)
Antineoplastic Agent <br> Paclitaxel 6 mg / mL<br> Intravenous Injection <br>Multiple Dose Vial 25 mL <br> teva 00703476701
![Paclitaxel (Pazenir) 5 mg/ml Powder for Dispersion for Infusion - Summary of Product Characteristics (SmPC) - (emc) Paclitaxel (Pazenir) 5 mg/ml Powder for Dispersion for Infusion - Summary of Product Characteristics (SmPC) - (emc)](https://www.medicines.org.uk/emc/images/spc/spc~38882~4~184905A.png)